A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Clinical trial NCT03298516 · COMPLETED
Trial details
- NCT number
- NCT03298516
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-15
- Primary completion
- 2019-07-16
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.